Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on December 17, 2021, to report significant amendments to its Memorandum and Articles of Association. These changes are primarily driven by the company's successful initial public offering (IPO) on the Shanghai Stock Exchange's Science and Technology Innovation Board (STAR Market). The amendments aim to align the company's governance with Chinese securities regulations and enhance operational flexibility for its dual-listed shares. Key updates include modifications to share transfer procedures to accommodate electronic transfers recognized by the STAR Market, and new provisions for holding general meetings, allowing for physical, hybrid, or electronic formats to better facilitate shareholder participation, especially for those holding Renminbi (RMB) shares. Notably, the company has also established the U.S. federal district courts as the exclusive forum for resolving disputes related to the U.S. Securities Act of 1933, a common practice for companies with significant U.S. investor bases.
Key Highlights
- 1BeiGene, Ltd. (ONC) amended its Memorandum and Articles of Association, effective December 15, 2021.
- 2These amendments were necessary to comply with regulations related to its IPO on the Shanghai Stock Exchange's STAR Market.
- 3Share transfer requirements have been updated to recognize electronic transfers as valid, facilitating trading on the STAR Market.
- 4The company can now hold general meetings in physical, hybrid, or electronic formats.
- 5Shareholders of RMB Shares will have facilitated access to attend general meetings via an online voting platform, considered presence in person.
- 6U.S. federal district courts are designated as the exclusive forum for resolving claims under the U.S. Securities Act of 1933, unless the company consents otherwise.
- 7The filing also confirms the closing of BeiGene's RMB 22.2 billion (US$3.5 billion) IPO on the STAR Market.